Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001049810 | Cervix | CC | proteasomal protein catabolic process | 111/2311 | 490/18723 | 8.98e-11 | 1.58e-08 | 111 |
GO:00510904 | Cervix | CC | regulation of DNA-binding transcription factor activity | 87/2311 | 440/18723 | 4.85e-06 | 1.22e-04 | 87 |
GO:00507273 | Cervix | CC | regulation of inflammatory response | 75/2311 | 386/18723 | 3.95e-05 | 6.18e-04 | 75 |
GO:00510915 | Cervix | CC | positive regulation of DNA-binding transcription factor activity | 51/2311 | 260/18723 | 5.05e-04 | 4.92e-03 | 51 |
GO:00510923 | Cervix | CC | positive regulation of NF-kappaB transcription factor activity | 32/2311 | 152/18723 | 1.62e-03 | 1.25e-02 | 32 |
GO:005072711 | Cervix | HSIL_HPV | regulation of inflammatory response | 41/737 | 386/18723 | 8.30e-09 | 1.03e-06 | 41 |
GO:005109211 | Cervix | HSIL_HPV | positive regulation of NF-kappaB transcription factor activity | 20/737 | 152/18723 | 2.25e-06 | 9.41e-05 | 20 |
GO:005109012 | Cervix | HSIL_HPV | regulation of DNA-binding transcription factor activity | 35/737 | 440/18723 | 6.77e-05 | 1.58e-03 | 35 |
GO:005109112 | Cervix | HSIL_HPV | positive regulation of DNA-binding transcription factor activity | 24/737 | 260/18723 | 1.01e-04 | 2.16e-03 | 24 |
GO:001049826 | Esophagus | HGIN | proteasomal protein catabolic process | 139/2587 | 490/18723 | 1.20e-17 | 3.41e-15 | 139 |
GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
GO:00510908 | Esophagus | ESCC | regulation of DNA-binding transcription factor activity | 252/8552 | 440/18723 | 5.22e-07 | 6.97e-06 | 252 |
GO:00510918 | Esophagus | ESCC | positive regulation of DNA-binding transcription factor activity | 155/8552 | 260/18723 | 3.83e-06 | 4.14e-05 | 155 |
GO:00510926 | Esophagus | ESCC | positive regulation of NF-kappaB transcription factor activity | 91/8552 | 152/18723 | 2.91e-04 | 1.75e-03 | 91 |
GO:001049812 | Liver | Cirrhotic | proteasomal protein catabolic process | 216/4634 | 490/18723 | 2.52e-21 | 9.29e-19 | 216 |
GO:001049822 | Liver | HCC | proteasomal protein catabolic process | 351/7958 | 490/18723 | 6.92e-40 | 1.46e-36 | 351 |
GO:00510902 | Liver | HCC | regulation of DNA-binding transcription factor activity | 220/7958 | 440/18723 | 8.04e-04 | 4.82e-03 | 220 |
GO:00510913 | Liver | HCC | positive regulation of DNA-binding transcription factor activity | 131/7958 | 260/18723 | 5.98e-03 | 2.45e-02 | 131 |
GO:00104988 | Lung | IAC | proteasomal protein catabolic process | 90/2061 | 490/18723 | 6.69e-07 | 3.89e-05 | 90 |
GO:00510903 | Lung | IAC | regulation of DNA-binding transcription factor activity | 76/2061 | 440/18723 | 4.44e-05 | 1.05e-03 | 76 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PSMA6 | SNV | Missense_Mutation | | c.253G>T | p.Ala85Ser | p.A85S | P60900 | protein_coding | deleterious(0.04) | possibly_damaging(0.506) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
PSMA6 | SNV | Missense_Mutation | rs267603983 | c.506G>A | p.Gly169Glu | p.G169E | P60900 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PSMA6 | SNV | Missense_Mutation | novel | c.355N>T | p.Ala119Ser | p.A119S | P60900 | protein_coding | deleterious(0.02) | benign(0.432) | TCGA-C5-A8ZZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | Cisplatin | SD |
PSMA6 | deletion | Frame_Shift_Del | | c.539delN | p.Val183Ter | p.V183* | P60900 | protein_coding | | | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PSMA6 | SNV | Missense_Mutation | rs760361768 | c.386N>T | p.Ala129Val | p.A129V | P60900 | protein_coding | deleterious(0.02) | probably_damaging(0.938) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD |
PSMA6 | SNV | Missense_Mutation | rs752794747 | c.503C>T | p.Ala168Val | p.A168V | P60900 | protein_coding | tolerated(0.4) | benign(0.006) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PSMA6 | SNV | Missense_Mutation | novel | c.4T>C | p.Ser2Pro | p.S2P | P60900 | protein_coding | deleterious(0) | probably_damaging(0.939) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PSMA6 | SNV | Missense_Mutation | novel | c.400N>A | p.Leu134Ile | p.L134I | P60900 | protein_coding | deleterious(0.01) | possibly_damaging(0.908) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
PSMA6 | deletion | Frame_Shift_Del | | c.546delA | p.Val183Ter | p.V183* | P60900 | protein_coding | | | TCGA-B5-A0JZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
PSMA6 | deletion | Frame_Shift_Del | | c.539delN | p.Val183Ter | p.V183* | P60900 | protein_coding | | | TCGA-D1-A0ZS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5687 | PSMA6 | PROTEASE, DRUGGABLE GENOME | inhibitor | CHEMBL451887 | CARFILZOMIB | |
5687 | PSMA6 | PROTEASE, DRUGGABLE GENOME | inhibitor | CARFILZOMIB | CARFILZOMIB | |
5687 | PSMA6 | PROTEASE, DRUGGABLE GENOME | inhibitor | CHEMBL2103884 | OPROZOMIB | |
5687 | PSMA6 | PROTEASE, DRUGGABLE GENOME | inhibitor | CHEMBL325041 | BORTEZOMIB | |
5687 | PSMA6 | PROTEASE, DRUGGABLE GENOME | inhibitor | CHEMBL371405 | MARIZOMIB | |
5687 | PSMA6 | PROTEASE, DRUGGABLE GENOME | | CARFILZOMIB | CARFILZOMIB | 24524217 |
5687 | PSMA6 | PROTEASE, DRUGGABLE GENOME | inhibitor | CHEMBL3545432 | IXAZOMIB CITRATE | |
5687 | PSMA6 | PROTEASE, DRUGGABLE GENOME | | BORTEZOMIB | BORTEZOMIB | 24524217 |
5687 | PSMA6 | PROTEASE, DRUGGABLE GENOME | inhibitor | BORTEZOMIB | BORTEZOMIB | |